Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 4/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.39 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.34 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.34 |
| ▸ | TACR1 | P25103 | 2/20 | 0.34 |
| ▸ | TACR3 | P29371 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2087342 | 0.89 | GPR119 (0.41) | NR3C1GPR119LPAR5DYRK1ADYRK2 | |
| SCHEMBL2087359 | 0.85 | MAP4K4 (0.42) | NR3C1GPR119MAPTDYRK1ADYRK2 | |
| SCHEMBL2055588 | 0.84 | GPR119 (0.38) | NR3C1GPR119MAPTRECQLDYRK1A | |
| SCHEMBL2087112 | 0.81 | GPR119 (0.36) | NR3C1GPR119MAPTRECQLDYRK1A | |
| SCHEMBL2084115 | 0.80 | CNR2 (0.39) | GPR119MAPTTACR1TACR3 | |
| SCHEMBL2055577 | 0.80 | NR3C1 (0.39) | NR3C1GPR119MAPTRECQLGPBAR1 | |
| SCHEMBL2085513 | 0.80 | GPR119 (0.46) | GPR119MAPT | |
| SCHEMBL4108340 | 0.80 | PTGDR2 (0.38) | GPR119GPBAR1TACR1TACR3 | |
| SCHEMBL2085685 | 0.79 | GPR119 (0.43) | NR3C1GPR119MAPT | |
| SCHEMBL2085486 | 0.79 | GABRP (0.46) | GPR119MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188097-B2 | Pyrazolo[1,5-A]pyrimidine compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-05-29 | — | — | US | disclosed |
| US-20090069298-A1 | Pyrazolo[1,5-A]Pyrimidine Compounds | TANABE SEIYAKU CO., LTD. (JP) | 2009-03-12 | — | — | US | disclosed |
| EP-1945220-A1 | PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CANNABINOID RECEPTOR ANTAGONISTS | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007046548-A1 | PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CANNABINOID RECEPTOR ANTAGONISTS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069298-A1 | Pyrazolo[1,5-A]Pyrimidine Compounds | RECQL, QTRT1, DPYD | NR3C1 1629/4885GPR119 2137/4885LPAR5 2861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.